News

Statistically significant reductions in serum ferritin, transferrin saturation index, and iron levels were observed after treatment, with hyperferritinemia eradicated in nearly all patients treated with DAAs achieving SVR.

Investigators studying over 4500 patients with gram-negative bacteremia see opportunities for earlier transition from IV to oral antibiotics.

The week's news included the differences in public attitudes towards influenza and COVID-19 vaccines, sex-based differences in direct-acting antivirals, a request for an emergency use authorization for a monoclonal antibody for COVID-19 prevention in the immunocompromised, and our final episode of our RSV Roundtable series, which has clinicians weighing in on the importance of counseling patients on the immunizations now and their significance for the future.

The panel discusses the importance of discussing the immunizations with patients now, as well as the value of them in future seasons.

Recall affects several raw bulk products sent to restaurants and institutional users, and are marked either angus ground beef patties, ground beef patties, or ground beef.

Results of a study by Yan Xie and colleagues highlight the severe impact of COVID-19, with higher death rates, increased risks of long-term complications, and greater infectivity compared to seasonal influenza.

A study used real-world CDC data to calculate the number of people who needed to be vaccinated to prevent both medical events in the greater community.

In 43 of 154 school weeks, air samples were positive for influenza A virus (IAV) while SARS-CoV-2 was positive in air samples in 101 of 154 school weeks.

Biopharmaceutical company, Invivyd, made the request to the FDA for its investigational antibody, VYD222.

In a new survey, respondents said both vaccines were efficacious, but a higher share said influenza vaccines were very safe compared to COVID-19 vaccines. This demonstrates a public health concern considering the higher incidence rates and hospitalizations of COVID-19 over the flu, and the possibility of low vaccine intakes.

New and novel antimicrobials remain at a crossroads as the path to development and economic viability continue to be serious challenges. Our Editor-in-Chief weighs in on this topic and some of the other most significant ones from this past year.

Although no differences were observed in the safety and efficacy of FDA-approved combination DAA therapies, female participants reported numerically more adverse events than male participants.

In the fourth installment of RSV Roundtable, our panel explains the challenges in protecting the senior population against RSV.

This year saw the approval of new therapies as well as the continued evolution of time-to-treat infections and updated guidelines.

A study utilizing this technology identified specific predictive factors for developing hepatitis in diabetic patients.

In 2023, there were numerous developments in hepatitis C including the Biden Administration's new budget that put aside several billion dollars towards establishing a hepatitis C (HCV) program; the Cherokee Nation's Hepatitis C elimination program which has worked to increase screening and get people into the continuum of care; and how one clinician is bringing HCV care to the streets through her mobile clinics. Check out these stories and more from this year.

The current treatment pathway might need to evolve to adjust to rapid diagnostics and narrowing down the antibiotics to aid in optimal outcomes for sicker patients with gram-negative infections.

The first self-amplifying mRNA COVID-19 vaccine was approved in Japan; how email reminders fared in encouraging people with diabetes to get their influenza vaccines; in the latest RSV Roundtable, our panel discusses the addition of nirsevimab; and a biotech company is focused on the detection and diagnosis of viral diseases, with a particular interest in Long COVID.

In the third installment of RSV Roundtable, our panel discusses the impact nirsevimab has had this RSV season.

United Kingdom-based Virax Biolabs is a biotech company that is focused on the detection and diagnosis of viral diseases, with a particular interest in the enigmatic, Long COVID.

Early treatment of the antiviral tecovirimat (TPOXX) could inhibit virus replication by more than 90%.

Analysis of the NUDGE-FLU study reveals electronic nudges designed to boost influenza vaccination were more effective in older adults without diabetes, highlighting the need for tailored approaches in diabetes populations.

The company, RNAimmune, got the ok from the FDA for its vaccine, RV-1770.

The company’s investigational V116 vaccine covers 21 serotypes, and if approved, it would be the first pneumococcal conjugate vaccine specifically designed for adults.

The data from these meta-analyses highlight the value of developing systems to promote daily toothbrushing among those who have been hospitalized and, particularly, those on mechanical ventilation.

Topline data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile infection (CDI) vaccine.

The 2 recalls were performed due to concerns about salmonella in the former and lead in the latter.

Investigational 24-valent pneumococcal conjugate vaccine developed on cell-free protein synthesis platform is first to broaden coverage without reduced immunogenicity.